{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:19:34Z","timestamp":1764260374001,"version":"3.38.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). These post hoc exposure\u2013response (E\u2013R) analyses of pooled data from two Phase 3 studies (NCT01877668 and NCT01882439) characterized the relationships between tofacitinib exposure and efficacy (American College of Rheumatology [ACR] criteria), and changes in hemoglobin (Hgb) in patients with PsA. Efficacy data for the proportion of patients receiving tofacitinib 5 or 10 mg twice daily, or placebo, achieving ACR \u226520%, \u226550%, or \u226570% response criteria (ACR20, ACR50, and ACR70, respectively) at Month 3, were modeled jointly using a four\u2010category ordered categorical exposure\u2013response model (ACR20 non\u2010responder, ACR20 responder but not ACR50 responder, ACR50 responder but not ACR70 responder, and ACR70 responder). A maximum drug effect (E<jats:sub>max<\/jats:sub>) model (using average concentrations of tofacitinib at steady state [C<jats:sub>avg<\/jats:sub>]) adequately described the exposure\u2013ACR response rate relationship. Model\u2010predicted response rates for tofacitinib 5 and 10 mg twice daily were 51% and 58%, respectively, for ACR20; 29% and 36% for ACR50; and 15% and 20% for ACR70. The E\u2013R relationship between tofacitinib exposure and changes in Hgb was assessed using an indirect response model, which generally predicted Hgb concentration\u2013time profiles across treatments well. The proportions of patients experiencing a decrease in Hgb of &gt;2 g\/dL were similar with tofacitinib 5 mg twice daily or placebo. These results were generally consistent with previous analyses in rheumatoid arthritis and psoriasis, and support the use of tofacitinib 5 mg twice daily for active PsA.<\/jats:p>","DOI":"10.1002\/jcph.6147","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T16:09:56Z","timestamp":1729872596000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exposure\u2013Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results from Two Phase 3 Studies"],"prefix":"10.1002","volume":"65","author":[{"given":"Sujatha","family":"Menon","sequence":"first","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shoji","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Tsuchiwata","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[{"name":"Pfizer Canada  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Kanik","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes324"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.003"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00010-2"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30339-8"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203516"},{"volume-title":"XELJANZ\u00ae (tofacitinib): highlights of prescribing information","year":"2024","author":"US Food and Drug Administration","key":"e_1_2_10_18_1"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.01.003"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.401"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.576"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.22"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2601"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.54"},{"issue":"1","key":"e_1_2_10_26_1","first-page":"S94","article-title":"Development and application of a model\u2010based decision criterion for a laboratory endpoint to facilitate tofacitinib (CP\u2010690,550) phase 3 dose selection","volume":"91","author":"Gupta P","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061691"},{"volume-title":"NONMEM User's Guides (1989\u20132009)","year":"2009","author":"Beal S","key":"e_1_2_10_28_1"},{"volume-title":"The R Project for Statistical Computing","author":"The R Foundation","key":"e_1_2_10_29_1"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9361-x"},{"volume-title":"Poster 738 presented at the 14th Annual Meeting of the Population Approach Group in Europe","year":"2005","author":"Holford N","key":"e_1_2_10_33_1"},{"volume-title":"Poster 1434 presented at the 17th Annual Meeting of the Population Approach Group in Europe","year":"2008","author":"Karlsson MO","key":"e_1_2_10_34_1"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.013"},{"volume-title":"Assessment report: Xeljanz, International non\u2010proprietary name: tofacitinib","year":"2018","author":"European Medicines Agency","key":"e_1_2_10_39_1"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12182"},{"volume-title":"Assessment report: Xeljanz, International non\u2010proprietary name: tofacitinib","year":"2017","author":"European Medicines Agency","key":"e_1_2_10_41_1"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.6147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:11:17Z","timestamp":1741767077000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.6147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/jcph.6147"],"URL":"https:\/\/doi.org\/10.1002\/jcph.6147","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"2024-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}